» Articles » PMID: 38679930

Causal Interpretation of the Hazard Ratio in Randomized Clinical Trials

Overview
Journal Clin Trials
Publisher Sage Publications
Date 2024 Apr 29
PMID 38679930
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although the hazard ratio has no straightforward causal interpretation, clinical trialists commonly use it as a measure of treatment effect.

Methods: We review the definition and examples of causal estimands. We discuss the causal interpretation of the hazard ratio from a two-arm randomized clinical trial, and the implications of proportional hazards assumptions in the context of potential outcomes. We illustrate the application of these concepts in a synthetic model and in a model of the time-varying effects of COVID-19 vaccination.

Results: We define causal estimands as having either an or interpretation. Difference-in-expectation estimands are both individual-level and population-level estimands, whereas without strong untestable assumptions the causal rate ratio and hazard ratio have only population-level interpretations. We caution users against making an incorrect individual-level interpretation, emphasizing that in general a hazard ratio does not on average change each individual's hazard by a factor. We discuss a potentially valid interpretation of the constant hazard ratio as a population-level causal effect under the proportional hazards assumption.

Conclusion: We conclude that the population-level hazard ratio remains a useful estimand, but one must interpret it with appropriate attention to the underlying causal model. This is especially important for interpreting hazard ratios over time.

Citing Articles

Inverse Probability of Treatment Weighting Using the Propensity Score With Competing Risks in Survival Analysis.

Austin P, Fine J Stat Med. 2025; 44(5):e70009.

PMID: 39915951 PMC: 11803134. DOI: 10.1002/sim.70009.


Reply to Heitjan's commentary.

Fay M, Li F Clin Trials. 2024; 21(5):638-639.

PMID: 38679936 PMC: 11502287. DOI: 10.1177/17407745241243311.

References
1.
Wang B, Ogburn E, Rosenblum M . Analysis of covariance in randomized trials: More precision and valid confidence intervals, without model assumptions. Biometrics. 2019; 75(4):1391-1400. DOI: 10.1111/biom.13062. View

2.
Karrison T . Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations. Control Clin Trials. 1997; 18(2):151-67. DOI: 10.1016/s0197-2456(96)00089-x. View

3.
Klein J, Logan B, Harhoff M, Andersen P . Analyzing survival curves at a fixed point in time. Stat Med. 2007; 26(24):4505-19. DOI: 10.1002/sim.2864. View

4.
Zeger S, Liang K, Albert P . Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988; 44(4):1049-60. View

5.
Cheng C, Li F, Thomas L, Li F . Addressing Extreme Propensity Scores in Estimating Counterfactual Survival Functions via the Overlap Weights. Am J Epidemiol. 2022; 191(6):1140-1151. DOI: 10.1093/aje/kwac043. View